HomeAbout usTeamInvestor relationsPress releasesMediaCedar Psychiatry Cedar Clinical Research CareersFAQContact

Investor relations

We are a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites.

CSE:NM

Novamind Inc.

Share capitalization
Issued & outstanding: 41,482,017
Reserved for issuance: 1,281,250
Dilutive securities: 6,325,292

Canadian Securities Exchange
Latest Novamind
presentationView presentation
Latest Novamind
fact sheetView fact sheet

Press releases

View all

May 04, 2021

Novamind Doubles in Size, Adds Four New Psychedelic Mental Health Clinics

April 21, 2021

Novamind Collaborates with Center for Change

April 19, 2021

Novamind to Present at the Planet MicroCap Virtual Event on April 22, 2021

April 13, 2021

Novamind Increases Strategic Investment in Bionomics

Financial statements

YearQuarterDateReportDownload
2021Q2March 1, 2021Interim Financial Statements View PDF
2021Q2March 1, 2021Management’s Discussion and Analysis View PDF

Interim Financial Statements

March 1, 2021

View PDF

Q2 • 2021

Management’s Discussion and Analysis

March 1, 2021

View PDF

Q2 • 2021

Fiscal year end is June 30th. To view Novamind's full financial disclosures, please visit SEDAR

Advisors

Transfer agent

Marrelli Trust Company Limited

Legal Counsel

McMillan LLP

Auditor

DMCL LLP

Interested in investing? Contact IR@novamind.ca

Sign up for our newsletter

Get our latest press releases and round ups of Novamind news and media delivered right to your inbox.